New antibody KBA1412 tested in patients with Hard-to-Treat cancers
Disease control
Completed
This early-phase trial tested a new drug called KBA1412, a lab-made antibody that targets a protein on cancer cells. It was given alone or with another cancer drug (pembrolizumab) to 16 adults with advanced solid tumors that had stopped responding to standard treatments. The main…
Phase: PHASE1 • Sponsor: Kling Biotherapeutics B.V. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC